Investor Ideas #Potcasts 530, #Cannabis News and #Stocks on the Move; (TSX: $TGOD.TO) (OTC: $TGODF) (NYSE: $ACB) (TSX: $ACB.TO) (TSX: $VLNS.TO) (OTCQX: $VLNCF)
Delta, Kelowna, BC, February 12, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
https://www.investorideas.com/Audio/Podcasts/2021/021221-StocksToWatch.mp3
Read this in full
at https://www.investorideas.com/news/2021/cannabis-potcasts/02121TGOD-ACB-VLNS.asp
Hear the investor ideas potcast on Spotify
Hear Investor ideas cannabis potcast on iTunes
Today’s podcast overview/transcript:
Good
afternoon and welcome to another episode of Investorideas.com
"Potcast" featuring cannabis news, stocks to watch as well as
insights from thought leaders and experts.
In
today’s podcast we will be looking at a few public and private company
announcements.
The
Green Organic Dutchman Holdings Ltd. (TSX:
TGOD) (OTC:
TGODF), a leading producer of premium certified organically
grown cannabis, announced that it
has signed a supply agreement with CannMart, a subsidiary of Namaste
Technologies Inc., making its certified organic medical cannabis products
available via CannMart's online medical cannabis sales platform.
"Working with established
players such as CannMart expands our distribution footprint within the medical
cannabis market, while allowing TGOD to focus medical resources on research and
innovation," commented Sean Bovingdon, TGOD's Chief Financial Officer and
Interim Chief Executive Officer.
"Their reach and scale facilitate access to cannabis treatments for
patients across Canada."
"We are pleased to welcome TGOD
to CannMart.com and look forward to working closely with them to expand their
reach to Canadian cannabis consumers," commented Chad Agate, CTO and VP,
Marketplace of Namaste Technologies. "We continue to leverage our Marketplace
Platform, VendorLink, as we are increasingly seeing the added value Namaste's
innovative technology can bring to organizations such as TGOD."
Under the two-year term agreement,
TGOD will provide CannMart with a broad portfolio of certified organic medical
cannabis products, including premium dried flower, RIPPLE dissolvable powder,
gummies, and teas.
Ikänik
Farms Inc. announced that
its wholly owned, Colombian subsidiary Pideka SAS ("Pideka"), has
successfully completed the first commercial sale and exportation of THC or
tetrahydrocannabinol, (the psychoactive ingredient in cannabis) to Mexico, for
use in Formula Magistral.
"We are excited to participate
in this groundbreaking moment for the cannabis industry and the countries of
Mexico and Colombia, as the first Colombian company to export psychoactive
cannabis oil to Mexico. We would like to thank both governments for their
roles, ensuring this collaborative effort remained a top priority." said
Borja Sanz de Madrid, President of Ikänik Farms, International.
Working hand in hand with both
governments, the Company was successfully able to obtain all certifications and
permissions, needed to legalize the process and complete its 15-step procedure
required to export psychoactive cannabis products from Colombia to Mexico.
Ikänik Farms legalized the
exportation process of psychoactive cannabis in Colombia, making it the first
company to successfully complete a "commercial sale" for export.
Looking ahead, the company will
provide cannabinoid solutions through formula magistral in LATAM to treat
epilepsy, cancer, pain, nausea, anxiety, insomnia and support the growing
demand of the EU marketplace.
"We are proud to have
participated in this historic moment and look forward to our growth, servicing
the global cannabis market." said Brian Baca, CEO of Ikänik Farms.
Ikänik Farms intends to list on the
Canadian Securities Exchange.
Canadian neurotech start-up Zentrela today
announced the completion of an $850K seed round led by Jornic
Ventures.
The investment will be used to
further commercialize Zentrela's proprietary EEG test for cannabis impairment
and create the world's largest scientific database of cannabis product
effects1. In 2019 the company raised $1.2M in funding from the Ontario Brain
Institute and various government agencies to fund prototype development and
clinical trials.
The neuroscience of cannabis is
advancing quickly at pace with the speed of deregulation, as government
regulators, license producers, drug testing experts, law enforcement officials
and recreational cannabis users seek to better understand cannabis and its
effects on the brain.
"Our research has already
identified several proprietary signatures related to how cannabis impacts the
brain. We are now cataloguing the entire universe of effects for Cannabis 2.0
products. This goldmine of data will help unlock new insights and opportunities
for licensed producers and enable cannabis consumers to make more informed
purchase decisions to ensure responsible and enjoyable cannabis use," says
Israel Gasperin, Zentrela CEO and founder.
"We expect innovative cannabis
2.0 products will trigger the next wave of growth in the cannabis sector,
especially as US markets continue to deregulate and the prospect of national US
legalization becomes more real," says Richard Sansom, President of Jornic
Ventures. "Zentrela's unique and scalable neuroscience-based methodology
solves a major challenge for the industry and promises to provide a rapidly growing
universe of cannabis users with the information they demand and need safe and
enjoyable cannabis use."
Zentrela's approach combines
proprietary artificial intelligence algorithms with deep neuroscience expertise
to decode electrical brain activity and convert it into reliable and meaningful
information.
"The potential for neuroscience
has exploded as artificial intelligence and machine learning algorithms have
matured. We can now isolate neural 'signatures' of product effects and use that
information rapidly to accelerate the process of mapping specific cannabis
product effects for consumers," says Gasperin.
High
Tea Cannabis Co. announced the
opening of its flagship cannabis store in Brampton, Ontario and its commitment
to achieving zero-emission delivery by utilizing its fleet of Tesla vehicles.
High Tea will open its doors to the
public officially on February 12, 2021 with some clear market differentiators
at play that will appeal to its customers.
“Prior to the pandemic, visions for
High Tea included a space that moved beyond just cannabis retail but included
social, experiential interactions and integrative wellness offerings that would
distinguish our brand from other retailers in the space,” said Paul Joo, CEO of
High Tea Cannabis Co. “However, amid the pandemic, we have put these social
integrations aside for the moment and will instead focus on grounding the customer
experience through premium cannabis offerings, reliable delivery and curbside
pickup.”
While the social and interactive
components may not be available at the outset, High Tea will still be setting
itself apart through its unique delivery vehicles, where more than half of the
fleet will be operating via Tesla cars.
“Growth in e-commerce has meant that
there are more delivery vehicles on the road than ever before, and we want to
do our part to reduce our carbon footprint. High Tea is committed to sustainability
and our goal is to expand our availability of Tesla vehicles and achieve
zero-emissions delivery for all orders in the future,” said Joo.
Located inside Kennedy Square Mall,
High Tea will be adding much-needed offerings to the budding community of
Brampton. Today, more than 600,000 residents call Brampton home with
significant population growth expected year over year. Despite this annual
population growth, there are only five legal cannabis stores in this area
today.
“We see great potential for High Tea
to thrive in Brampton while simultaneously offering tremendous value to the
community that lives there. We had very clear characteristics that we were
looking for when selecting the location for our flagship store, and Brampton
hit each element including a thriving population, space for opportunity and
diversity,” said Joo.
Effective February 12th, High Tea
will offer fast and convenient delivery to Brampton, Georgetown, Milton,
Mississauga, and Vaughan. To celebrate the opening of its flagship store, High
Tea will offer $5 delivery to all accessible regions..
This is the first location for the
High Tea brand but the company is poised to open an additional fifteen stores
in 2021 in Ontario.
Aurora Cannabis Inc. (NYSE:
ACB)
(TSX:
ACB),
the Canadian company defining the future of cannabinoids worldwide,
today announced its financial and operational results for
the second quarter of fiscal 2021 ended December 31, 2020.
Some of
their financial highlights included: Total Cannabis Net Revenue of $70.3
Million, Excluding Provisions of $2.7 Million, Up 11% over Q2 2020; Medical
Cannabis Net Revenue of $38.9 Million, Up 42% Versus Q2 2020, Driven by a 562%
Increase in High Margin International Medical Sales; and Adjusted EBITDA Loss,
excluding Provisions and Termination Costs, of $12.1 Million Represents an
Improvement of $53.1 Million Over Q2 2020; Current Loss Triggered by Several
Decisions Expected to Boost Long-Term Profitability.
"Aurora
had an excellent second quarter, and I'm pleased that we're advancing nicely
against the plan we laid out in September of 2020," stated Miguel Martin,
Chief Executive Officer of Aurora Cannabis. "For the period, our core
revenue strength in medical and consumer was complemented by initial rollouts
in vape products and concentrates. Combined, these elements are part of the
proven, regulated CPG strategy we've adopted.
Adjusted EBITDA for the quarter, while vastly improved year over year,
was impacted by several decisions that we believe will clear a path for our
premium product focus and more variable cost model. We are confident that this
will give Aurora maximum flexibility and position the organization to drive
significant cashflow in the coming quarters."
"To
further support this strategy, we have also focused on improving our cash burn,
margins and overall financial flexibility.
To that point, our year over year cash use has decreased by 74% to $70.5
million, our normalized margins remain solid particularly in medical, and our
recently amended credit facility gives Aurora much improved optionality as
opportunities arise. Combined with $565
million in cash on our balance sheet today, Aurora will continue to be a
long-term player in the global cannabinoid market and increasingly positioned
to deliver for shareholders over the long run."
The
Valens Company Inc. (TSX:
VLNS) (OTCQX:
VLNCF), a leading manufacturer of cannabis derivative
products, has
received an amendment to its existing Health Canada standard
processing licence permitting the sale of dried cannabis products to authorized
provincial and territorial retailers in Canada. This licence amendment allows
The Valens Company to distribute next generation dried cannabis derivative
products across the country, increasing the Company's total addressable market.
Pre-rolls and dried cannabis
derivative products will be the latest additions to the Company's growing
portfolio of in-demand offerings, which includes a variety of cannabis extract
products such as vapes, concentrates, edibles, beverages, and topicals. With
this new licence, The Valens Company can now offer a complete range of products
to its customers in the Canadian recreational cannabis market.
"At the request of our partners
we are increasing our product offering to include pre-rolls and next generation
dried cannabis products," said Tyler Robson, Chief Executive Officer,
Co-Founder and Chair of The Valens Company. "We believe that this licence,
paired with our low-cost platform, will drive a competitive advantage for our
partners in a category with price sensitive consumers."
With access to competitively priced
fresh and dried cannabis sources, Valens is strongly positioned to develop and
manufacture the highest-quality dried cannabis derivative products at a
category shaping value proposition. A variety of pre-roll formats, in numerous
blends and sizes, are currently under development at Valens' newly-operational
K2 facility located in Kelowna, British Columbia.
ATMA
Journey Centers Inc. ("ATMA"), an Alberta-based
company focused on delivering innovative psychedelic-assisted therapies
internationally, announced
today the launch of an innovative professional training
program in conjunction with Wayfound Mental Health Group Inc.
("Wayfound") that will equip mental health professionals with the
knowledge and insight to work with psychedelic medicines as they become
accessible and legalized in Canada.
Starting in March 2021, ATMA and
Wayfound will present the Psychedelic Therapy Training Program for Mental
Health Professionals, which will take place through remote training as well as
on-site at ATMA's Calgary Journey Center.
The training allows participants to apply for an exemption from Health
Canada to experience legal psychedelic-assisted therapy using psilocybin, one
of the active compounds found in 'magic mushrooms'. Incorporating hands-on experience with
psychedelics for therapists in a legal setting is a first for the mental health
community in Canada.
David Harder, Co-CEO of ATMA, said:
"While Health Canada continues to increase access to legal
psychedelic-assisted therapy for patients through their recent Section 56
Exemptions, there is a growing need in the mental health industry for
therapists to have the appropriate training and knowledge to facilitate this
important work."
Each participant of the professional
training program will also be assisted in obtaining their own exemption from
Health Canada so that they may personally undergo psychedelic-assisted therapy.
This unique element of the training will
provide each professional the personal perspective to truly understand and
experience how psychedelics can benefit their patients.
Health Canada has recently been
taking steps to increase access to psychedelic medicine through its ongoing
approvals of exemptions under Section 56 of the Controlled Drugs and Substances
Act (CDSA), the legislation that governs controlled substances in Canada such
as psychedelics. ATMA was the first
private company in Canada to conduct legal psychedelic-assisted therapy using
psilocybin on behalf of a palliative client who had been granted a Section 56
exemption.
Health Canada also recently
completed a public consultation period regarding the Special Access Program
(SAP), with a view to reversing certain regulatory changes made in 2013 that
prohibited access to restricted drugs (such as psychedelics) through the SAP.
Added Harder: "We believe that
Health Canada has recognized the need to consider increased access to
psychedelic medicine for Canadians, and that a key element of this will be
ensuring that there are professionals prepared and trained to support patients
who undergo this innovative treatment."
The Psychedelic Therapy Training
Program will commence in March and will feature a world-class faculty of
instructors and practitioners that represent many of the leaders in the global
psychedelic medicine community.
Confirmed instructors include Dr. Rick Doblin, Founder and Executive
Director of MAPS, a U.S. based organization widely considered to be the most
influential player in the growing psychedelics renaissance.
Harder noted: "We've seen
extraordinary interest and response in this initial program, and we anticipate
that this will be the first of many trainings we offer in the coming
months. Our first group is almost at
capacity already, so we're working hard to expand our programming calendar to
respond to the need."
Investor ideas reminds all
listeners to read our disclaimers and disclosures on the Investorideas.com
website and that this podcast is not an endorsement to buy products or services
or securities. Investors are reminded all investment involves risk and possible
loss of investment.
Learn more about
our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
Investors can trade these stocks and other ideas on our site using our list of top stock trading apps
including Robinhood , Acorn, Stash and
others.
To hear more
Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
Investorideas.com
podcasts are also available on iTunes,
Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified
word mark Trademark on the blockchain through Cognate, Inc. CM
Certification-Registration Number: 10468217708
About Investorideas.com - News that
Inspires Big Investing Ideas
Investorideas.com
is a recognized news source publishing third party news, research and original
financial content. Learn about investing in stocks and sector trends with our
news alerts, articles, podcasts and
videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water,
renewable energy and more. Investor Idea’s original branded content includes
the following podcasts and columns : Crypto Corner , Play
by Play sports and stock news column, Investor Ideas
Potcasts Cannabis News and Stocks on the Move podcast and
column, Cleantech
and Climate Change , Exploring
Mining the AI
Eye .
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and
equity research as well as creates original content, including video,
interviews and articles. Original content created by investorideas is protected
by copyright laws other than syndication rights. Our site does not make
recommendations for purchases or sale of stocks, services or products. Nothing
on our sites should be construed as an offer or solicitation to buy or sell
products or securities. All investing involves risk and possible losses. This
site is currently compensated for news publication and distribution, social
media and marketing, content creation and more. Disclosure is posted for each
compensated news release, content published /created if required but otherwise
the news was not compensated for and was published for the sole interest of our
readers and followers. Contact management and IR of each company directly
regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other
news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations
of each country. Please read Investorideas.com privacy policy:
https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of
cannabis except where permissible by law. Our site does not possess,
distribute, or sell cannabis products.
Follow us on Twitter https://twitter.com/Investorideas
Follow
us on Facebook https://www.facebook.com/Investorideas
Follow
us on YouTube https://www.youtube.com/c/Investorideas
Download
our Mobile App for
iPhone and Android
Join
our Investor Club https://www.investorideas.com/membership/
Contact Investorideas.com
800
665 0411
Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directory
